COMP <GO>
ONCO vs ERNA // EV/EBITDA & P/E VALUATION
Onconetix Inc. (NASDAQ) VS. Ernexa Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ONCO 2
— ERNA 0
■ METRIC PARITY
LAST: $0.59 (-1.99%) • MKT CAP: $3.5M
valuation
—
LAST: $2.11 (+6.57%) • MKT CAP: $3.4M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONCO VS. ERNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONCO | ERNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 32.3 | +16.01 | ONCO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.5M | $3.4M | $13.0K | ONCO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONCO REV | ERNA REV | ONCO GROSS % | ERNA GROSS % | ONCO FCF | ERNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $815.4K | $0 | 77.6% | — | -$9.7M | -$7.1M |
| FY 2024 | $2.5M | $582.0K | 41.8% | 83.5% | -$10.5M | -$16.2M |
| FY 2023 | $58.5K | $68.0K | — | — | -$13.6M | -$20.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONCO // BETA —
ERNA // BETA —